Background Interpretation of the evidence from randomised controlled trials (RCTs) of
remdesivir in patients treated in hospital for COVID-19 is conflicting. We aimed to assess the …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel virus that spread
worldwide from 2019 causing the Coronavirus disease 19 (COVID-19) pandemic. SARS …

Summary COVID-19, caused by SARS-CoV-2, is characterised by a broad spectrum of
symptom severity that requires varying amounts of care according to the different stages of …

Background We aimed to evaluate the use of baricitinib, a Janus kinase (JAK) 1–2 inhibitor,
for the treatment of patients admitted to hospital with COVID-19. Methods This randomised …

Background Tixagevimab–cilgavimab is a neutralising monoclonal antibody combination
hypothesised to improve outcomes for patients hospitalised with COVID-19. We aimed to …

The clinical implications of COVID-19 have changed since SARS-CoV-2 first emerged in
humans. The current high levels of population immunity, due to prior infection and/or …

Thromboembolism is a common and deadly consequence of COVID-19 infection for
hospitalized patients. Based on clinical evidence pre-dating the COVID-19 pandemic and …

Background Randomized controlled trials (RCT) established the mortality reduction by
tocilizumab (Actemra), baricitinib (Olumiant), and sarilumab (Kevzara) in hospitalized COVID …

The therapeutic potential of sotrovimab in the treatment of coronavirus disease 2019 (COVID‐
19) is a controversial issue. The aim of this study was to evaluate the efficacy and safety of …

Platelet–endothelial interactions have a critical role in microcirculatory function, which
maintains tissue homeostasis. The subtle equilibrium between platelets and the vessel wall …